CJC-1295
Long-acting growth-hormone-releasing hormone analog studied for effects on growth hormone signaling.
Editorial review: August 13, 2026Evidence snapshot
This drawer marks papers. It is not a plan, a dose, or a source. A paper is a bounded report. It is not a protocol. Grades name the object. They are not a safety rating.
Identity first. Literature and gray-market naming confuse CJC-1295 with DAC (Drug Affinity Complex; albumin-binding, long-acting GHRH analog) with CJC-1295 without DAC / Mod GRF 1-29 (tetrasubstituted GHRH 1-29 amide without the DAC linker). Those are different objects. Do not badge a single CJC CAS — CAS strings collide across with-DAC and without-DAC synonym lists. Name the analog. Human PK/PD papers in this set describe the long-acting, albumin-binding analog (with DAC). Do not read them as evidence for the without-DAC peptide. CJC-1295 is not approved. Off-label does not apply. There is no label to be off of.
Bottom line
Thin but real human PK/PD exists for CJC-1295 with DAC: healthy-adult trials show prolonged GH and IGF-I rises and preserved GH pulsatility after the long-acting analog. That is a GH-axis stimulation object in healthy volunteers — not an approved indication, not body composition, not anti-aging, and not proof for without-DAC / Mod GRF 1-29. Preclinical growth rescue appears in a GHRH-knockout mouse paper on the same long-acting analog. Detection/doping papers are not efficacy. Without-DAC human intervention evidence in this set is essentially absent.
Papers
Early human — CJC-1295 with DAC (albumin-binding long-acting analog)
PMID 16352683 — Teichman 2006
Tested: CJC-1295 (long-acting GHRH analog that binds albumin; reported multi-day half-life) versus placebo in healthy adults — ascending single-dose and multi-dose PK/PD for GH and IGF-I.
Does not show: an approved therapeutic use, a body-composition or performance claim, or results for CJC-1295 without DAC / Mod GRF 1-29.
PMID 17018654 — Ionescu 2006
Tested: overnight GH pulsatility in healthy young men before and after a single injection of the same long-acting CJC-1295 analog; trough/mean GH and IGF-I.
Does not show: a disease-treatment trial, or that without-DAC Mod GRF produces the same multi-day profile.
PMID 19386527 — Sackmann-Sala 2009
Tested: serum proteomic changes in healthy young men one week after CJC-1295 (long-acting GHRH analog) injection; exploratory GH/IGF-I action biomarkers.
Does not show: clinical benefit, an approved use, or a without-DAC result. Small n.
Preclinical — CJC-1295 with DAC
PMID 16822960 — Alba 2006
Tested: once-daily CJC-1295 (long-acting GHRH analog) in GHRH knockout mice for growth normalization.
Does not show: a human growth or adult-body-composition result.
Context, not a grade — detection / naming noise
PMID 21871962, 26879649, 34665524, 35298973
Tested: analytical detection of GHRH analogs (including CJC-1295-class peptides) in doping-control matrices.
Does not show: human therapeutic efficacy. Presence in a urine screen is not a clinical endpoint.
Tested: narrative review of performance-enhancing peptides modulating the GH–IGF-I axis; clinical evidence is described as limited relative to marketing.
Does not show: a new controlled human CJC-1295 trial.
What this set does not contain
No verified human PK/PD or efficacy RCT in this set for CJC-1295 without DAC / Mod GRF 1-29 as a cleanly labeled object. Do not substitute Teichman/Ionescu for that identity.
What is not established
Any approved indication. Body fat, muscle, recovery, or “anti-aging” as human treatment claims. Equivalence of with-DAC and without-DAC products. Identity between trial material and any circulating vial. Product labels that say “CJC-1295” without stating DAC status are ambiguous — mark the paper’s actual analog, not the shop name.
Selected sources
16352683 17018654 19386527 16822960 21871962 26879649 34665524 35298973 42395176
Reported experiences
Sleep, recovery, body composition
Reported topics are not established benefits.Risks and unknowns
Hormonal effects, swelling, headache, glucose changes, product quality
Compare experiences with care.
Join the discussion
Verified members can contribute to compound conversations.